Marketing Your Business
Keywords and Search Results

I was in the Warriors forum today and someone was proudly boasting he had his site at no one in Google for his local cleaning company. but he complained his description was rubbish.

The reason being he had forgotten to add metatags to his site. Without metatags Google does not know what you want to display. you must remember to spend a little time setting up metatags on any site where you have access.

Google and other search engines are always seeking to present the results you are searching for, which is great however you need to ensure that when you are researching keywords or looking to find on what page your site appears to log out of application such as Google+.

For many years I have had a top ranking site for Lose Weight USA usually in the top 3 out of 80M but if I am logged into Google+ I have positions 2,3,4 and I also show as position 10 for weight loss with 210M results…great for the ego but not for business.

Matters can be further complicated by using local searches say for the Philippines where of course by site would not appear in results.

Another useful tool to use when researching keywords is Google Trends, which follow news items in this case you can clearly seen that items about weight loss are growing in popularity

Not shown here are the links to the news items concerned, which one can follow in order to create extra content for your daily posts.

David Ogden

Veretekk Trainer

1-386-308-1956 (24 hours)

davidogdens [@] gmail.com

Skype seadogs11
Office Hours-6AM-12AM GMT +8

Top SEO Results Tools  |  RSS  |  Conference Room  |  Videos  |  Contact Me

The information in this medication sheet has been adapted from the FDA-approved prescribing information for Gilenya.
Description

Gilenya™ is a new class of medication called a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Gilenya was evaluated in two large-scale, phase III clinical trials involving people with relapsing-remitting MS:

In a two-year study (FREEDOMS) comparing two doses of Gilenya to placebo, Gilenya (at the lower, 0.5mg dose) reduced relapses by 54% and reduced the risk of disability progression by 30% compared to placebo. Gilenya also reduced brain lesion activity as measured by MRI.
In a one-year study (TRANSFORMS) comparing two doses of Gilenya to interferon beta-1a (Avonex), Gilenya (at the lower, 0.5mg dose) reduced relapses by 52% compared with Avonex; reduced disease activity as measured by the number of new and newly enlarged T2 lesions on MRI scans compared with Avonex (1.6 vs 2.6, respectively at one year); reduced brain lesion activity as measured by MRI.

In August 2011, the FDA approved an update in the prescribing information for Gilenya to include the MRI findings from both the TRANSFORMS and FREEDOMS studies. In both clinical trials, Gilenya showed a reduction in gadolinium-enhancing lesions, which indicate new MS activity. The data from the TRANSFORMS study indicated that at 12 months, the mean number of gadolinium-enhancing T1 lesions was significantly lower for patients treated with Gilenya at the 0.5 mg dose than for patients taking interferon beta-1a (Avonex), 0.2 vs 0.5 respectively. In the FREEDOMS trial, the mean number of gadolinium-enhancing T1 lesions was significantly lower at 24 months for the group treated with Gilenya (0.5 mg dose) than for the placebo group, 0.2 vs 1.1.

Gilenya has not been studied in people under the age of 18.

Approval by the U.S. Food and Drug Administration (FDA)

Gilenya was approved by the U.S. Food and Drug Administration (FDA) in 2010 for adults with relapsing forms of MS to reduce the frequency of clinical relapses and to delay the accumulation of physical disability.

http://www.youtube.com/watch?v=JSJaDWheyGk&feature=colike

In April, 2012, the FDA (along with the European Medicines Agency — EMA) revised the prescribing information for Gilenya based on independent safety reviews initiated by the agencies after deaths had been reported among patients taking Gilenya. The revised prescribing information defines who should avoid using this MS therapy based on pre-existing medical conditions, and alters the recommended testing and heart monitoring that occurs when the first dose is given:

All those starting treatment with Gilenya should have an electrocardiogram prior to dosing and after the 6-hour observation period. During the observation period, blood pressure and heart rate should be measured hourly.

People whose first-dose monitoring indicates potentially unsafe heart events may require longer monitoring, and any who require treatment for low heart rate during the first-dose monitoring will need to be monitored overnight.

Gilenya is not advisable for people who have had a history or presence of specific heart and vascular conditions, including heart attack, stroke, and heartbeat irregularities, and people taking heart rate-lowering medication.

If anyone with a pre-existing heart condition is started on Gilenya, after the first dose the patient should be monitored overnight with continuous electrocardiogram in a medical facility.
The heart function monitoring applies only to people initiating their first dose, and not to people who are already taking daily doses of Gilenya. There are also revised recommendations for people who re-initiate treatment after discontinuing Gilenya. People should not make changes to their Gilenya therapy without consulting their prescriber.

http://www.youtube.com/watch?v=lUS5Tiq5O28&feature=colike

Macular Edema:

Oral MS Drug May Increase Risk for Macular Edema
A report from the North American Neuro-Ophthalmology Society (NANOS) and the AAO

ONE Neuro-Ophthalmology Committee

*ONE Neuro-ophthalmology chair: Andrew G. Lee, MD for the ONE Committee
Data from recent multinational Phase 2 and 3 clinical trials of fingolimod (Gilenya, Novartis) suggest an association of the agent to a low risk of cystoid macular edema (CME). Fingolimod is the first oral medication approved by the U.S. FDA for relapsing forms of MS and is an immunomodulator that regulates lymphocyte distribution, reducing lymphocyte recirculation from lymphoid tissue to blood and peripheral tissues. A two-year FDA clinical trial compared fingolimod with placebo and another one-year trial compared fingolimod with interferon beta-1a.

Although several clinical trials to date have shown fingolimod to be well tolerated, side effects have included bradycardia, headache, upper respiratory tract infection, shortness of breath, diarrhea and nausea. In the two-year trial, macular edema occurred in 0.4 percent of patients treated with fingolimod and 0.1 percent who received the placebo.

Study patients were monitored with medical histories, visual acuity, contrast sensitivity, dilated ophthalmoscopy, optical coherence tomography (OCT), and had ophthalmic examinations at 1, 3, 6, 12 and 18 months.
Compared to placebo, Fingolimod reduced the MS relapse rate and increased the percentage of patients without a MS relapse in both studies. The differences were statistically significant.

http://www.youtube.com/watch?v=i7hG_YS1WiE&feature=colike

Transient bradycardia, HTN

Because of the risk of transient bradycardias and heart block after the first dose, the recommended level of cardiovascular monitoring of all patients after their first dose of fingolimod has now increased as outlined here

Fingolimod (Gilenya▼) is authorised to treat relapsing-remitting multiple sclerosis in patients whose disease has failed to respond to beta-interferon or is severe and getting worse rapidly. It is a sphingosine-1 phosphate receptor modulator.

Fingolimod is known to cause transient bradycardias and might be associated with atrioventricular block after the first dose; these are reflected in existing recommendations to observe patients for signs and symptoms of bradycardia in the 6 hours post administration.

The European Medicines Agency (EMA) has started a review of the benefits and risks of fingolimod after becoming aware of new post-marketing evidence about its possible cardiovascular effects after taking the first dose. This includes a 59-year-old patient from the USA with multiple sclerosis who died within 24 hours of taking the first dose of Gilenya. This patient was being treated with metoprolol and amlodipine for hypertension.

The exact cause of death is currently unknown. In addition to the unexplained death in the USA, six other unexplained deaths (including three cases of sudden death) after starting treatment with fingolimod have also been reported. As at Feb 6, 2012, we have received four UK reports of suspected adverse reactions with fingolimod, including one case of bradycardia and hypotension occurring 4 hours after the first dose with a drop in heart rate experienced again the following day.

While the review of fingolimod is ongoing, the EMA’s Committee for Medicinal Products for Human Use now recommends that the level of cardiovascular monitoring of all patients is increased after their first dose of fingolimod:

Patients that are taking this drug have to be watched and check on redularly with their Doctors. Their care has to be writen down and saved for research.

http://www.youtube.com/watch?v=L7UvhwORTd4&feature=colike
This is just some of the side effects of Fingloimod in the treatment of Multiple Sclerosis.

James Eckburg
Senior Health and Wellness Strategist
www.Jamescornershop.com,
www.eckburgjoe.veretekk.com

114 E. Franklin St.
Lanark, Illinois 61046
skype: jamesoeck1
joeckburg@gmail.com

The Three Faces of Fatigue with Multiple Sclerosis

I would like to talk about tree facesof Fatigue: One is Physical, Second one is Mental, and the Third one Emotional. The first one is Physical is extremely comon. Fatigue strikes about four out of five people with Multiple Sclerosis and it is so real. “Multiple Sclerosi fatigueis genuine and has a biologial basis”, that Lauren Krupp, MD, Professor of Neureology and Diretor of Neuropsychology research center at Stony Brook University Medical Center in New Yourk.

Multiple Sclerosis fatigue can be distinguished from the garden-variety fatigue when it si abnormally severe, but there are markers that a person has with Multiple Sclerosis. Fatigue temds to accur daily and they can aome on suddenly without much worning. You may feel grood in the morning when you get up and than in middle morning you feel very tired and you have had a good nights sleep. Than as the day goes on you get very tired or fatigue. When it gets very hot and humid is the worst time for me.

Why do I get so tired??

The Primary Multiple Sclerosis fatigue is casused by frayed nerve fibers wearing out easily. You see nerve damage to the vast computer system of the brain causes misfires and split-second dekays in impulse transmissions, this was said by George Kraft, MD, MS Alvord Professor of Research at the University of Washington Medical Center in Seattle.

You will see that your walking becomes more difficult, your speach will slurs and your mind clouds and overtaxed nervous system burns through fuel like aragged motor. YOu see that Fatigue is like a fuel gauge telling you the tank is empty.

Your Secondary energy-sappers include not enough sleep or quality sleep, depression, medication, stress, pain, being out of shape, and the sheer increase inengery used to get around and get things done.

Given the nature of MS, it is expected that central fatigue contributes to fatigue perceived by MS patients.22 Central fatigue is commonly measured with the twitch-interpolated technique during a maximal contraction. The underlying principle is relatively simple.23 During an MVC, a stimulus is given to the appropriate nerve or muscle. If participants activate their muscles maximally, no increase in force is evoked by this stimulus. During a submaximal activation, however, an extra force is evoked.

The size of the interpolated twitch gives a measure of the voluntary activation, and an increase over time reflects central fatigue.8 However, during a sustained contraction, the evoked twitch tends to decline as a result of fatigue-related changes in the periphery. Because the amount of peripheral fatigue differs between MS patients and controls,10,14 it is necessary to correct for peripheral fatigue. Studies that investigated the association between perceived fatigue and central fatigue in MS patients did not always correct for peripheral fatigue.

http://www.youtube.com/watch?v=O3iXoh3fh7w&feature=colike

http://www.youtube.com/watch?v=VQFrmW3K9Bk&feature=colike

Though the casuses of fatigue are understood it is not clear why differentpeople exercise fatigueso differently. Luca Roccatagliata, MD, PhD, and his Neuriscience colleagues at the University of Genoa speculate that anatomical changes tothe brain exist in a complex biological network that is different in every person. That is another reson why Multiple Sclerosis isso diffcult to diagnois. Thus so even tiny bit of damage in the front part of your brain called the frontal lobes can causean action to interact badly with the helathier part of your brain in the healthy deeper part of your brain. Thus so it iwll enhance the nature and preception of fatigue in some unique way.

J. Lamar Freed, Psy.D. wrote anarticle on Understanding the Unique Role Of Fatigue In Multiple Sclerosis:

Yet despite this recognition I do not believe fatigue has been taken as seriously nor viewed as profoundly as what the experience of people with MS merits. Fatigue is a symptom of MS. But is so much more than that. Fatigue underlies and influences a great many of the other symptoms experienced by people with MS.

The essential mechanism of MS is that the Brain’s Myelin covered nerve cells that communicate the commands and information from one part of the Brain to another or to other parts of the body are impeded or blocked by the destruction of the Myelin sheath which surrounds and insulates the cells.

These communication cells serve as the superhighway that makes these messages travel quickly and easily. This means that for the information to travel properly when the Myelin has been destroyed or damaged it must bully through on less efficient channels, or go around on other channels that may not be ideally constructed for the task.

It’s like getting from New York to Washington without driving on I-95. Depending on the locations and number of these Myelin depleting lesions, communication within the Brain can be profoundly disrupted. Like with drives that last too long, fatigue is one of the results.

Fatigue is experienced both physically and mentally. It is sometimes easily evident because of a feeling of general tiredness and it can also be overlooked.

It can show itself immediately and it can be delayed, at times for days. Its primary treatment is rest. And like everything else about MS, it is highly variable from one person to the next.

Physical fatigue is often experienced as a bone numbing tiredness. It is a tiredness that belays description. It can make movement seem impossible and the requirement for movement overwhelming.Yet despite this recognition I do not believe fatigue has been taken as seriously nor viewed as profoundly as what the experience of people with MS merits. Fatigue is a symptom of MS. But is so much more than that. Fatigue underlies and influences a great many of the other symptoms experienced by people with MS.
The essential mechanism of MS is that the Brain’s Myelin covered nerve cells that communicate the commands and information from one part of the Brain to another or to other parts of the body are impeded or blocked by the destruction of the Myelin sheath which surrounds and insulates the cells.
These communication cells serve as the superhighway that makes these messages travel quickly and easily. This means that for the information to travel properly when the Myelin has been destroyed or damaged it must bully through on less efficient channels, or go around on other channels that may not be ideally constructed for the task.
It’s like getting from New York to Washington without driving on I-95. Depending on the locations and number of these Myelin depleting lesions, communication within the Brain can be profoundly disrupted. Like with drives that last too long, fatigue is one of the results.
Fatigue is experienced both physically and mentally. It is sometimes easily evident because of a feeling of general tiredness and it can also be overlooked.
It can show itself immediately and it can be delayed, at times for days. Its primary treatment is rest. And like everything else about MS, it is highly variable from one person to the next.Yet despite this recognition I do not believe fatigue has been taken as seriously nor viewed as profoundly as what the experience of people with MS merits. Fatigue is a symptom of MS. But is so much more than that. Fatigue underlies and influences a great many of the other symptoms experienced by people with MS.
The essential mechanism of MS is that the Brain’s Myelin covered nerve cells that communicate the commands and information from one part of the Brain to another or to other parts of the body are impeded or blocked by the destruction of the Myelin sheath which surrounds and insulates the cells.
These communication cells serve as the superhighway that makes these messages travel quickly and easily. This means that for the information to travel properly when the Myelin has been destroyed or damaged it must bully through on less efficient channels, or go around on other channels that may not be ideally constructed for the task.
It’s like getting from New York to Washington without driving on I-95. Depending on the locations and number of these Myelin depleting lesions, communication within the Brain can be profoundly disrupted. Like with drives that last too long, fatigue is one of the results.
Fatigue is experienced both physically and mentally. It is sometimes easily evident because of a feeling of general tiredness and it can also be overlooked.
It can show itself immediately and it can be delayed, at times for days. Its primary treatment is rest. And like everything else about MS, it is highly variable from one person to the next.Yet despite this recognition I do not believe fatigue has been taken as seriously nor viewed as profoundly as what the experience of people with MS merits. Fatigue is a symptom of MS. But is so much more than that. Fatigue underlies and influences a great many of the other symptoms experienced by people with MS.
The essential mechanism of MS is that the Brain’s Myelin covered nerve cells that communicate the commands and information from one part of the Brain to another or to other parts of the body are impeded or blocked by the destruction of the Myelin sheath which surrounds and insulates the cells.
These communication cells serve as the superhighway that makes these messages travel quickly and easily. This means that for the information to travel properly when the Myelin has been destroyed or damaged it must bully through on less efficient channels, or go around on other channels that may not be ideally constructed for the task.
It’s like getting from New York to Washington without driving on I-95. Depending on the locations and number of these Myelin depleting lesions, communication within the Brain can be profoundly disrupted. Like with drives that last too long, fatigue is one of the results.
Fatigue is experienced both physically and mentally. It is sometimes easily evident because of a feeling of general tiredness and it can also be overlooked.
It can show itself immediately and it can be delayed, at times for days. Its primary treatment is rest. And like everything else about MS, it is highly variable from one person to the next.
Physical fatigue is often experienced as a bone numbing tiredness. It is a tiredness that belays description. It can make movement seem impossible and the requirement for movement overwhelming.

James Eckburg
Senior Health and Wellness Strategist
www.Jamescornershop.com,
www.eckburgjoe.veretekk.com

114 E. Franklin St.
Lanark, Illinois 61046
skype: jamesoeck1
joeckburg@gmail.com

Nopalea Cactus Juice

Controlling stress and inflammation

Sometimes, we can be overwhelmed by the various types of stress that come with everyday life. These include mental stress, such as over-work; physical stress, such as exercising more than usual; emotional stress, as when we’re having relationship problems, and environmental stress from pollutants in our environment and food supply.

Today let’s look at just one type of stress — emotional — to see how the brain and body respond. Suppose you get a letter from the government tax office saying you owe 40,000. Even if you have that kind of cash lying around, you’re going to feel stressed. Your brain will release chemicals called catecholamines that trigger inflammatory processes. One might be the release of insulin, a pro-inflammatory hormone.

Too much stress over an extended time period will cause insulin resistance, which is associated with obesity. That obesity (which itself creates inflammation) triggers the body to produce another pro-inflammatory hormone called cortisol, which creates more stress, and so on and so on. Clearly, then, controlling stress will help break this cycle of inflammation, and help the body return to its natural, balanced state.

Keys to stress management
The first step toward managing stress is to identify the things in your life that are causing it: marital problems, work pressures or illness in the family. Once you identify and understand these stressors, you can begin to find ways to change your environment and manage them. Support groups, exercise and certain nutritional supplements may help modify the levels of stress hormones and help the mind and body to re-balance.

David Ogden

CEO TheInterbiz LLC

1-386-308-1956 (24 hours)

trivita [@] theinterbiz.com

Office Hours-6AM-12AM GMT +8